Xiaojing Wang

7PUBLICATIONS
31CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Proteins and peptidesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 17, 2026
Optimization and In Vivo Characterization of a Series of Cbl‑b Inactive-State Inhibitors.

|Feb 05, 2025
Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis.

Xiaojing Wang

|Jun 01, 2023
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.

Sarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo

|Apr 20, 2022
Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors.

Kristin M Zimmerman Savill, Brian B Lee, Jason Oeh

|Feb 05, 2019
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.

Xiaojing Wang, Wesley Blackaby, Vivienne Allen

|Feb 20, 2018
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

James J Crawford, Adam R Johnson, Dinah L Misner

Pageof 2

Frequent Collaborators

2 joint publications

Georgette M Castanedo

1 joint publications

James J Crawford

1 joint publications

Joseph W Lubach

1 joint publications

Jeremy Murray